PD trials demonstrated that GLP-1RAs may have disease-modifying potential through their effects on insulin, Akt, and mTOR signaling pathways in the brain, which are involved in the neurodegenerative process [49]. The gene discussed is AKT1; the disease is Parkinson disease.